Protocol Ledger

NCT04652102 · Phase II/III · COMPLETED

A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older

Interventional Phase II/III clinical trial protocol NCT04652102 sponsored by CureVac in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-12-11 Enrollment: 39,680 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04652102
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)39,680 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04652102
Protocol FieldVerified Registry Value
NCT IdentifierNCT04652102
Consolidated Lead SponsorCureVac
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II/III
Overall Recruitment StatusCOMPLETED
Registered Enrollment39,680 participants (ACTUAL)
Registered Start Date2020-12-11
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04652102
Hospital Research SiteLocationSite Profile
Universitair Ziekenhuis GentGhent, BelgiumOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI